APO Research
Talk to an analyst

APO RESEARCH · REPORT

CGRP Monoclonal Antibodies

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global CGRP Monoclonal Antibodies Market Analysis and Forecast 2026-2032

27 December 2025193 pages

Choose your research edition.

Industry ResearchCGRP Monoclonal Antibodies Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal CGRP Monoclonal Antibodies Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal CGRP Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CGRP Monoclonal Antibodies Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal CGRP Monoclonal Antibodies Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global CGRP Monoclonal Antibodies market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CGRP Monoclonal Antibodies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for CGRP Monoclonal Antibodies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for CGRP Monoclonal Antibodies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for CGRP Monoclonal Antibodies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of CGRP Monoclonal Antibodies include Alder Therapeutics, Amgen Inc., Daiichi Sankyo Co., Ltd., Pfizer Inc., Lilly Inc., Lundbeck, Novartis International AG and Teva, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CGRP Monoclonal Antibodies, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CGRP Monoclonal Antibodies, also provides the revenue of main regions and countries. Of the upcoming market potential for CGRP Monoclonal Antibodies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CGRP Monoclonal Antibodies revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CGRP Monoclonal Antibodies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CGRP Monoclonal Antibodies revenue, projected growth trends, production technology, application and end-user industry.

CGRP Monoclonal Antibodies Segment by Company

Alder Therapeutics

Amgen Inc.

Daiichi Sankyo Co., Ltd.

Pfizer Inc.

Lilly Inc.

Lundbeck

Novartis International AG

Teva

CGRP Monoclonal Antibodies Segment by Type

Erenumab

Fremanezumab

Galcanezumab

Eptinezumab

CGRP Monoclonal Antibodies Segment by Application

Specialty Clinic

Hospital

Others

CGRP Monoclonal Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGRP Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CGRP Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGRP Monoclonal Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CGRP Monoclonal Antibodies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CGRP Monoclonal Antibodies company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CGRP Monoclonal Antibodies revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CGRP Monoclonal Antibodies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Erenumab Major Player Table 3. Fremanezumab Major Player Table 4. Galcanezumab Major Player Table 5. Eptinezumab Major Player Table 6. Global CGRP Monoclonal Antibodies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Specialty Clinic Major Player Table 8. Hospital Major Player Table 9. Others Major Player Table 10. CGRP Monoclonal Antibodies Industry Trends Table 11. CGRP Monoclonal Antibodies Industry Drivers Table 12. CGRP Monoclonal Antibodies Industry Opportunities and Challenges Table 13. CGRP Monoclonal Antibodies Industry Restraints Table 14. Global CGRP Monoclonal Antibodies Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global CGRP Monoclonal Antibodies Market Size by Region (2021-2026) & (US$ Million) Table 16. Global CGRP Monoclonal Antibodies Market Share by Region (2021-2026) Table 17. Global CGRP Monoclonal Antibodies Market Size by Region (2027-2032) & (US$ Million) Table 18. Global CGRP Monoclonal Antibodies Market Share by Region (2027-2032) Table 19. Global CGRP Monoclonal Antibodies Revenue by Players (US$ Million) & (2021-2026) Table 20. Global CGRP Monoclonal Antibodies Revenue Market Share by Players (2021-2026) Table 21. Global CGRP Monoclonal Antibodies Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global CGRP Monoclonal Antibodies Key Players Headquarters & Area Served Table 23. Global CGRP Monoclonal Antibodies Players, Product Type & Application Table 24. Global CGRP Monoclonal Antibodies Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global CGRP Monoclonal Antibodies by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global CGRP Monoclonal Antibodies Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global CGRP Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 29. Global CGRP Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 30. Global CGRP Monoclonal Antibodies Revenue Market Share by Type (2021-2026) Table 31. Global CGRP Monoclonal Antibodies Revenue Market Share by Type (2027-2032) Table 32. Global CGRP Monoclonal Antibodies Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global CGRP Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 34. Global CGRP Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 35. Global CGRP Monoclonal Antibodies Revenue Market Share by Application (2021-2026) Table 36. Global CGRP Monoclonal Antibodies Revenue Market Share by Application (2027-2032) Table 37. Alder Therapeutics Company Information Table 38. Alder Therapeutics Business Overview Table 39. Alder Therapeutics CGRP Monoclonal Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Alder Therapeutics CGRP Monoclonal Antibodies Product Portfolio Table 41. Alder Therapeutics Recent Development Table 42. Amgen Inc. Company Information Table 43. Amgen Inc. Business Overview Table 44. Amgen Inc. CGRP Monoclonal Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Amgen Inc. CGRP Monoclonal Antibodies Product Portfolio Table 46. Amgen Inc. Recent Development Table 47. Daiichi Sankyo Co., Ltd. Company Information Table 48. Daiichi Sankyo Co., Ltd. Business Overview Table 49. Daiichi Sankyo Co., Ltd. CGRP Monoclonal Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Daiichi Sankyo Co., Ltd. CGRP Monoclonal Antibodies Product Portfolio Table 51. Daiichi Sankyo Co., Ltd. Recent Development Table 52. Pfizer Inc. Company Information Table 53. Pfizer Inc. Business Overview Table 54. Pfizer Inc. CGRP Monoclonal Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Pfizer Inc. CGRP Monoclonal Antibodies Product Portfolio Table 56. Pfizer Inc. Recent Development Table 57. Lilly Inc. Company Information Table 58. Lilly Inc. Business Overview Table 59. Lilly Inc. CGRP Monoclonal Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Lilly Inc. CGRP Monoclonal Antibodies Product Portfolio Table 61. Lilly Inc. Recent Development Table 62. Lundbeck Company Information Table 63. Lundbeck Business Overview Table 64. Lundbeck CGRP Monoclonal Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Lundbeck CGRP Monoclonal Antibodies Product Portfolio Table 66. Lundbeck Recent Development Table 67. Novartis International AG Company Information Table 68. Novartis International AG Business Overview Table 69. Novartis International AG CGRP Monoclonal Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Novartis International AG CGRP Monoclonal Antibodies Product Portfolio Table 71. Novartis International AG Recent Development Table 72. Teva Company Information Table 73. Teva Business Overview Table 74. Teva CGRP Monoclonal Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Teva CGRP Monoclonal Antibodies Product Portfolio Table 76. Teva Recent Development Table 77. North America CGRP Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 78. North America CGRP Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 79. North America CGRP Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 80. North America CGRP Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 81. North America CGRP Monoclonal Antibodies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. North America CGRP Monoclonal Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 83. North America CGRP Monoclonal Antibodies Revenue by Country (US$ Million) & (2027-2032) Table 84. Europe CGRP Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 85. Europe CGRP Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 86. Europe CGRP Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 87. Europe CGRP Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 88. Europe CGRP Monoclonal Antibodies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Europe CGRP Monoclonal Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 90. Europe CGRP Monoclonal Antibodies Revenue by Country (US$ Million) & (2027-2032) Table 91. China CGRP Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 92. China CGRP Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 93. China CGRP Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 94. China CGRP Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 95. Asia CGRP Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 96. Asia CGRP Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 97. Asia CGRP Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 98. Asia CGRP Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 99. Asia CGRP Monoclonal Antibodies Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Asia CGRP Monoclonal Antibodies Revenue by Region (US$ Million) & (2021-2026) Table 101. Asia CGRP Monoclonal Antibodies Revenue by Region (US$ Million) & (2027-2032) Table 102. SAMEA CGRP Monoclonal Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 103. SAMEA CGRP Monoclonal Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 104. SAMEA CGRP Monoclonal Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 105. SAMEA CGRP Monoclonal Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 106. SAMEA CGRP Monoclonal Antibodies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. SAMEA CGRP Monoclonal Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 108. SAMEA CGRP Monoclonal Antibodies Revenue by Country (US$ Million) & (2027-2032) Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. CGRP Monoclonal Antibodies Image Figure 2. Global CGRP Monoclonal Antibodies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CGRP Monoclonal Antibodies Market Size Share 2021 VS 2025 VS 2032 Figure 4. Erenumab Image Figure 5. Fremanezumab Image Figure 6. Galcanezumab Image Figure 7. Eptinezumab Image Figure 8. Global CGRP Monoclonal Antibodies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global CGRP Monoclonal Antibodies Market Size Share 2021 VS 2025 VS 2032 Figure 10. Specialty Clinic Image Figure 11. Hospital Image Figure 12. Others Image Figure 13. Global CGRP Monoclonal Antibodies Market Size (US$ Million) & (2021-2032) Figure 14. Global CGRP Monoclonal Antibodies Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global CGRP Monoclonal Antibodies Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global CGRP Monoclonal Antibodies Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global CGRP Monoclonal Antibodies Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global CGRP Monoclonal Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global CGRP Monoclonal Antibodies Revenue Market Share by Type (2021-2032) Figure 21. Global CGRP Monoclonal Antibodies Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global CGRP Monoclonal Antibodies Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global CGRP Monoclonal Antibodies Revenue Market Share by Application (2021-2032) Figure 24. North America CGRP Monoclonal Antibodies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America CGRP Monoclonal Antibodies Revenue Share by Type (2021-2032) Figure 26. North America CGRP Monoclonal Antibodies Revenue Share by Application (2021-2032) Figure 27. North America CGRP Monoclonal Antibodies Revenue Share by Country (2021-2032) Figure 28. United States CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe CGRP Monoclonal Antibodies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe CGRP Monoclonal Antibodies Revenue Share by Type (2021-2032) Figure 33. Europe CGRP Monoclonal Antibodies Revenue Share by Application (2021-2032) Figure 34. Europe CGRP Monoclonal Antibodies Revenue Share by Country (2021-2032) Figure 35. Germany CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China CGRP Monoclonal Antibodies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China CGRP Monoclonal Antibodies Revenue Share by Type (2021-2032) Figure 45. China CGRP Monoclonal Antibodies Revenue Share by Application (2021-2032) Figure 46. Asia CGRP Monoclonal Antibodies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia CGRP Monoclonal Antibodies Revenue Share by Type (2021-2032) Figure 48. Asia CGRP Monoclonal Antibodies Revenue Share by Application (2021-2032) Figure 49. Asia CGRP Monoclonal Antibodies Revenue Share by Region (2021-2032) Figure 50. Japan CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA CGRP Monoclonal Antibodies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA CGRP Monoclonal Antibodies Revenue Share by Type (2021-2032) Figure 58. SAMEA CGRP Monoclonal Antibodies Revenue Share by Application (2021-2032) Figure 59. SAMEA CGRP Monoclonal Antibodies Revenue Share by Country (2021-2032) Figure 60. Brazil CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt CGRP Monoclonal Antibodies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Erenumab
  • Fremanezumab
  • Galcanezumab
  • Eptinezumab
Applications
  • Specialty Clinic
  • Hospital
  • Others
Companies covered
  • Alder Therapeutics
  • Amgen Inc.
  • Daiichi Sankyo Co., Ltd.
  • Pfizer Inc.
  • Lilly Inc.
  • Lundbeck
  • Novartis International AG
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CGRP Monoclonal Antibodies Market by Type
  3. 1.2.1 Global CGRP Monoclonal Antibodies Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Erenumab
  5. 1.2.3 Fremanezumab
  6. 1.2.4 Galcanezumab
  7. 1.2.5 Eptinezumab
  8. 1.3 CGRP Monoclonal Antibodies Market by Application
  9. 1.3.1 Global CGRP Monoclonal Antibodies Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Specialty Clinic
  11. 1.3.3 Hospital
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 CGRP Monoclonal Antibodies Market Dynamics
  1. 2.1 CGRP Monoclonal Antibodies Industry Trends
  2. 2.2 CGRP Monoclonal Antibodies Industry Drivers
  3. 2.3 CGRP Monoclonal Antibodies Industry Opportunities and Challenges
  4. 2.4 CGRP Monoclonal Antibodies Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CGRP Monoclonal Antibodies Market Perspective (2021-2032)
  2. 3.2 Global CGRP Monoclonal Antibodies Growth Trends by Region
  3. 3.2.1 Global CGRP Monoclonal Antibodies Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CGRP Monoclonal Antibodies Market Size by Region (2021-2026)
  5. 3.2.3 Global CGRP Monoclonal Antibodies Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CGRP Monoclonal Antibodies Revenue by Players
  2. 4.1.1 Global CGRP Monoclonal Antibodies Revenue by Players (2021-2026)
  3. 4.1.2 Global CGRP Monoclonal Antibodies Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CGRP Monoclonal Antibodies Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CGRP Monoclonal Antibodies Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CGRP Monoclonal Antibodies Key Players Headquarters & Area Served
  7. 4.4 Global CGRP Monoclonal Antibodies Players, Product Type & Application
  8. 4.5 Global CGRP Monoclonal Antibodies Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CGRP Monoclonal Antibodies Market CR5 and HHI
  11. 4.6.3 2025 CGRP Monoclonal Antibodies Tier 1, Tier 2, and Tier 3
5 CGRP Monoclonal Antibodies Market Size by Type
  1. 5.1 Global CGRP Monoclonal Antibodies Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CGRP Monoclonal Antibodies Revenue by Type (2021-2032)
  3. 5.3 Global CGRP Monoclonal Antibodies Revenue Market Share by Type (2021-2032)
6 CGRP Monoclonal Antibodies Market Size by Application
  1. 6.1 Global CGRP Monoclonal Antibodies Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CGRP Monoclonal Antibodies Revenue by Application (2021-2032)
  3. 6.3 Global CGRP Monoclonal Antibodies Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Alder Therapeutics
  2. 7.1.1 Alder Therapeutics Company Information
  3. 7.1.2 Alder Therapeutics Business Overview
  4. 7.1.3 Alder Therapeutics CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Alder Therapeutics CGRP Monoclonal Antibodies Product Portfolio
  6. 7.1.5 Alder Therapeutics Recent Developments
  7. 7.2 Amgen Inc.
  8. 7.2.1 Amgen Inc. Company Information
  9. 7.2.2 Amgen Inc. Business Overview
  10. 7.2.3 Amgen Inc. CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Amgen Inc. CGRP Monoclonal Antibodies Product Portfolio
  12. 7.2.5 Amgen Inc. Recent Developments
  13. 7.3 Daiichi Sankyo Co., Ltd.
  14. 7.3.1 Daiichi Sankyo Co., Ltd. Company Information
  15. 7.3.2 Daiichi Sankyo Co., Ltd. Business Overview
  16. 7.3.3 Daiichi Sankyo Co., Ltd. CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Daiichi Sankyo Co., Ltd. CGRP Monoclonal Antibodies Product Portfolio
  18. 7.3.5 Daiichi Sankyo Co., Ltd. Recent Developments
  19. 7.4 Pfizer Inc.
  20. 7.4.1 Pfizer Inc. Company Information
  21. 7.4.2 Pfizer Inc. Business Overview
  22. 7.4.3 Pfizer Inc. CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Inc. CGRP Monoclonal Antibodies Product Portfolio
  24. 7.4.5 Pfizer Inc. Recent Developments
  25. 7.5 Lilly Inc.
  26. 7.5.1 Lilly Inc. Company Information
  27. 7.5.2 Lilly Inc. Business Overview
  28. 7.5.3 Lilly Inc. CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Lilly Inc. CGRP Monoclonal Antibodies Product Portfolio
  30. 7.5.5 Lilly Inc. Recent Developments
  31. 7.6 Lundbeck
  32. 7.6.1 Lundbeck Company Information
  33. 7.6.2 Lundbeck Business Overview
  34. 7.6.3 Lundbeck CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Lundbeck CGRP Monoclonal Antibodies Product Portfolio
  36. 7.6.5 Lundbeck Recent Developments
  37. 7.7 Novartis International AG
  38. 7.7.1 Novartis International AG Company Information
  39. 7.7.2 Novartis International AG Business Overview
  40. 7.7.3 Novartis International AG CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Novartis International AG CGRP Monoclonal Antibodies Product Portfolio
  42. 7.7.5 Novartis International AG Recent Developments
  43. 7.8 Teva
  44. 7.8.1 Teva Company Information
  45. 7.8.2 Teva Business Overview
  46. 7.8.3 Teva CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Teva CGRP Monoclonal Antibodies Product Portfolio
  48. 7.8.5 Teva Recent Developments
8 North America
  1. 8.1 North America CGRP Monoclonal Antibodies Revenue (2021-2032)
  2. 8.2 North America CGRP Monoclonal Antibodies Revenue by Type (2021-2032)
  3. 8.2.1 North America CGRP Monoclonal Antibodies Revenue by Type (2021-2026)
  4. 8.2.2 North America CGRP Monoclonal Antibodies Revenue by Type (2027-2032)
  5. 8.3 North America CGRP Monoclonal Antibodies Revenue Share by Type (2021-2032)
  6. 8.4 North America CGRP Monoclonal Antibodies Revenue by Application (2021-2032)
  7. 8.4.1 North America CGRP Monoclonal Antibodies Revenue by Application (2021-2026)
  8. 8.4.2 North America CGRP Monoclonal Antibodies Revenue by Application (2027-2032)
  9. 8.5 North America CGRP Monoclonal Antibodies Revenue Share by Application (2021-2032)
  10. 8.6 North America CGRP Monoclonal Antibodies Revenue by Country
  11. 8.6.1 North America CGRP Monoclonal Antibodies Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CGRP Monoclonal Antibodies Revenue by Country (2021-2026)
  13. 8.6.3 North America CGRP Monoclonal Antibodies Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe CGRP Monoclonal Antibodies Revenue (2021-2032)
  2. 9.2 Europe CGRP Monoclonal Antibodies Revenue by Type (2021-2032)
  3. 9.2.1 Europe CGRP Monoclonal Antibodies Revenue by Type (2021-2026)
  4. 9.2.2 Europe CGRP Monoclonal Antibodies Revenue by Type (2027-2032)
  5. 9.3 Europe CGRP Monoclonal Antibodies Revenue Share by Type (2021-2032)
  6. 9.4 Europe CGRP Monoclonal Antibodies Revenue by Application (2021-2032)
  7. 9.4.1 Europe CGRP Monoclonal Antibodies Revenue by Application (2021-2026)
  8. 9.4.2 Europe CGRP Monoclonal Antibodies Revenue by Application (2027-2032)
  9. 9.5 Europe CGRP Monoclonal Antibodies Revenue Share by Application (2021-2032)
  10. 9.6 Europe CGRP Monoclonal Antibodies Revenue by Country
  11. 9.6.1 Europe CGRP Monoclonal Antibodies Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CGRP Monoclonal Antibodies Revenue by Country (2021-2026)
  13. 9.6.3 Europe CGRP Monoclonal Antibodies Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China CGRP Monoclonal Antibodies Revenue (2021-2032)
  2. 10.2 China CGRP Monoclonal Antibodies Revenue by Type (2021-2032)
  3. 10.2.1 China CGRP Monoclonal Antibodies Revenue by Type (2021-2026)
  4. 10.2.2 China CGRP Monoclonal Antibodies Revenue by Type (2027-2032)
  5. 10.3 China CGRP Monoclonal Antibodies Revenue Share by Type (2021-2032)
  6. 10.4 China CGRP Monoclonal Antibodies Revenue by Application (2021-2032)
  7. 10.4.1 China CGRP Monoclonal Antibodies Revenue by Application (2021-2026)
  8. 10.4.2 China CGRP Monoclonal Antibodies Revenue by Application (2027-2032)
  9. 10.5 China CGRP Monoclonal Antibodies Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CGRP Monoclonal Antibodies Revenue (2021-2032)
  2. 11.2 Asia CGRP Monoclonal Antibodies Revenue by Type (2021-2032)
  3. 11.2.1 Asia CGRP Monoclonal Antibodies Revenue by Type (2021-2026)
  4. 11.2.2 Asia CGRP Monoclonal Antibodies Revenue by Type (2027-2032)
  5. 11.3 Asia CGRP Monoclonal Antibodies Revenue Share by Type (2021-2032)
  6. 11.4 Asia CGRP Monoclonal Antibodies Revenue by Application (2021-2032)
  7. 11.4.1 Asia CGRP Monoclonal Antibodies Revenue by Application (2021-2026)
  8. 11.4.2 Asia CGRP Monoclonal Antibodies Revenue by Application (2027-2032)
  9. 11.5 Asia CGRP Monoclonal Antibodies Revenue Share by Application (2021-2032)
  10. 11.6 Asia CGRP Monoclonal Antibodies Revenue by Country
  11. 11.6.1 Asia CGRP Monoclonal Antibodies Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CGRP Monoclonal Antibodies Revenue by Country (2021-2026)
  13. 11.6.3 Asia CGRP Monoclonal Antibodies Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CGRP Monoclonal Antibodies Revenue (2021-2032)
  2. 12.2 SAMEA CGRP Monoclonal Antibodies Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CGRP Monoclonal Antibodies Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CGRP Monoclonal Antibodies Revenue by Type (2027-2032)
  5. 12.3 SAMEA CGRP Monoclonal Antibodies Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CGRP Monoclonal Antibodies Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CGRP Monoclonal Antibodies Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CGRP Monoclonal Antibodies Revenue by Application (2027-2032)
  9. 12.5 SAMEA CGRP Monoclonal Antibodies Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CGRP Monoclonal Antibodies Revenue by Country
  11. 12.6.1 SAMEA CGRP Monoclonal Antibodies Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CGRP Monoclonal Antibodies Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CGRP Monoclonal Antibodies Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst